Drug Patents owned by Veloxis Pharms Inc
1. List of Envarsus Xr drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8623410 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(1 year, 5 months from now) | |
| US8889185 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(1 year, 5 months from now) | |
| US9763920 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(1 year, 5 months from now) | |
| US8591946 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(1 year, 5 months from now) | |
| US8586084 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(1 year, 5 months from now) | |
| US11077096 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(1 year, 5 months from now) | |
| US8486993 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(1 year, 5 months from now) | |
| US9161907 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(1 year, 5 months from now) | |
| US8889186 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(1 year, 5 months from now) | |
| US8623411 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(1 year, 5 months from now) | |
| US10548880 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(1 year, 5 months from now) | |
| US7994214 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(1 year, 5 months from now) | |
| US9757362 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(1 year, 5 months from now) | |
| US8617599 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(1 year, 5 months from now) | |
| US10864199 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
May, 2028
(5 years from now) | |
| US11123331 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
May, 2028
(5 years from now) | |
| US11110081 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
May, 2028
(5 years from now) | |
| US9549918 | VELOXIS PHARMS INC | Stabilized tacrolimus composition |
May, 2028
(5 years from now) | |
| US10166190 | VELOXIS PHARMS INC | Stabilized tacrolimus composition |
May, 2028
(5 years from now) | |
| US11419823 | VELOXIS PHARMS INC | Stabilized tacrolimus composition |
May, 2028
(5 years from now) | |
| US8664239 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
Aug, 2028
(5 years from now) | |
| US8685998 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
Aug, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jul 10, 2022 |
Drugs and Companies using TACROLIMUS ingredient
Market Authorisation Date: 10 July, 2015
Treatment: Prophylaxis of organ rejection; Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; Prophylaxis of organ rejection in de novo transplant patient
Dosage: TABLET, EXTENDED RELEASE;ORAL
ENVARSUS XR family patents
33
United States
16
Denmark
4
Slovenia
4
Spain
4
Poland
4
Canada
4
European Union
3
Portugal
3
China
3
Japan
2
Austria
2
Australia
2
Lithuania
2
Hungary
2
Norway
2
Brazil
1
Hong Kong
1
Russia
1
Germany
1
Argentina
1
Korea, Republic of
1
Taiwan, Province of China
1
RS
1
EA
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic